Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerGlobeNewsWire • 04/16/24
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024InvestorPlace • 04/15/24
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.The Motley Fool • 04/10/24
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a TurnaroundZacks Investment Research • 04/03/24
All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to BuyZacks Investment Research • 04/01/24
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street AnalystThe Motley Fool • 03/07/24
Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease CommunityGlobeNewsWire • 03/01/24
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsGlobeNewsWire • 02/27/24
These 2 Healthcare Stocks Are in Nvidia's Portfolio. Should They Be in Yours?The Motley Fool • 02/22/24
Nvidia Just Invested in These 5 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.The Motley Fool • 02/21/24
Why Did Nvidia Invest in These 5 Artificial Intelligence (AI) Stocks? Should You Buy Them, Too?The Motley Fool • 02/20/24
Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/19/24